ADC Therapeutics SA - ADCT STOCK NEWS

ADC Therapeutics (NYSE:ADCT) announced the presentation of updated results from four clinical trials of ZYNLONTA™ (loncastuximab tesirine-lpyl) at the 16th Annual International Conference on Malignant Lymphoma (ICML). Key findings from the LOTIS-2 trial showed an overall response rate (ORR) of 48.3% and a median duration of response (mDoR) of 13.4 months in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The LOTIS-3 trial results reflected a 62.2% ORR when ZYNLONTA was combined with ibrutinib, with manageable toxicity. The company anticipates continued progress in ongoing clinical trials.

ADC Therapeutics (NYSE:ADCT) announced that shareholders approved all resolutions proposed at the Annual General Meeting (AGM). Key decisions include the election of Viviane Monges to the Board, who brings over 30 years of financial experience in the pharmaceutical sector.

The re-election of the current Board members and Compensation Committee was also confirmed, along with an increase in the maximum Board size to 12 members. Financial proposals were approved, including an increase in Authorized Share Capital by CHF 1,170,800, ensuring continued operational capacity for advancing ADC technology in cancer treatment.

ADC Therapeutics (NYSE:ADCT) announced that abstracts on camidanlumab tesirine (Cami) and ZYNLONTA™ (loncastuximab tesirine-lpyl) will be presented at the 16th Annual International Conference on Malignant Lymphoma from June 18-22, 2021. Cami's Phase 2 trial results for relapsed/refractory Hodgkin lymphoma will be shared in an oral presentation, while ZYNLONTA data will be discussed in both oral and poster formats for diffuse large B-cell lymphoma. The FDA has approved ZYNLONTA based on a notable 48.3% overall response rate in a pivotal clinical trial.

ADC Therapeutics SA (NYSE: ADCT) reported updated clinical data from the LOTIS-2 Phase 2 trial of ZYNLONTA™ for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) at the 2021 ASCO Annual Meeting. The results indicate a 48.3% overall response rate and a 24.8% complete response rate, with a median duration of response of 13.4 months. Notably, durable responses were observed in high-risk patients. No new safety concerns were identified, reinforcing ZYNLONTA's favorable safety profile. Regulatory approval from the FDA was granted based on these positive outcomes.

ADC Therapeutics (NYSE: ADCT) announced that CEO Chris Martin will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 8:30 a.m. ET. Investors can access a live webcast through the company's website, with a replay available for 30 days. ADC Therapeutics specializes in next-generation antibody drug conjugates (ADCs) for treating hematological malignancies and solid tumors. The company's FDA-approved ADC, ZYNLONTA™, targets relapsed diffuse large B-cell lymphoma, while Cami is under trial for Hodgkin lymphoma and advanced solid tumors.

ADC Therapeutics (NYSE:ADCT) announced that the Phase 1 clinical trial results of its anti-CD25 ADC, camidanlumab tesirine (Cami), have been published in The Lancet Haematology. The trial, involving 133 patients with relapsed or refractory Hodgkin and non-Hodgkin lymphomas, reported an overall response rate (ORR) of 58%, with a complete response rate of 29%. Heavily treated Hodgkin lymphoma patients showed an ORR of 71%. The study indicates Cami's potential as a treatment option for a significant unmet medical need. A pivotal Phase 2 trial is ongoing.

ADC Therapeutics SA (NYSE:ADCT) announced that three abstracts have been selected for poster presentations at the 2021 ASCO Annual Meeting, taking place virtually from June 4-8, 2021. The presentations will cover key research findings from their lead programs, highlighting the recent FDA approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) for treating relapsed or refractory large B-cell lymphoma. The FDA approval was based on a Phase 2 trial demonstrating a 48.3% overall response rate. ADC Therapeutics is advancing its pipeline of next-generation antibody drug conjugates for various cancers.

ADC Therapeutics (NYSE: ADCT) has secured a $50 million second tranche under its convertible credit facility with Deerfield Partners, following FDA's accelerated approval of ZYNLONTA™. This funding will bolster ADC Therapeutics' balance sheet and support the launch and development of its pipeline of next-generation antibody drug conjugates.

The company had previously received $65 million upon its IPO in May 2020, totaling $115 million from this facility. A Form F-3 registration statement will be filed with the SEC within 15 days, allowing Deerfield to sell shares if it opts to convert its notes.

ADC Therapeutics (NYSE: ADCT) has published results from the LOTIS-2 trial in The Lancet Oncology, demonstrating the efficacy of ZYNLONTA™ for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL). In this Phase 2 trial involving 145 patients, ZYNLONTA showed a 48.3% overall response rate, with a complete response rate of 24.1%. The median duration of response was 10.3 months. Despite some adverse events like neutropenia (25.5%), the study reinforces ZYNLONTA's potential as a standard treatment for DLBCL patients in need of new options, following FDA approval.